Clinical Assessment Sample Clauses

The Clinical Assessment clause defines the requirements and procedures for evaluating the safety, efficacy, and performance of a medical product or intervention in a clinical setting. It typically outlines the methods for collecting and analyzing clinical data, the roles and responsibilities of involved parties, and the standards that must be met during the assessment process. By establishing clear guidelines for clinical evaluation, this clause ensures that products are thoroughly vetted before use, thereby protecting patient safety and supporting regulatory compliance.
Clinical Assessment. 2.1 Medical assessment, 2.2 Risk Factors, 2.3 Symptoms, 2.4 Social Assessment.
View Source
Clinical Assessment. The patient in whom the novel missense variant p.R138Q was detected was contacted for clinical, genetic, and functional evaluations. All clinical assessments were carried out by a board-certified developmental pediatrician (▇. ▇▇▇▇▇▇▇▇▇) and a clinical geneticist/dysmorphologist (M. P. Adam). Genotyping of family members was performed with targeted Sanger sequencing. All genotyped family members gave informed consent to participate in this study. All aspects of the patient recontact and evaluation were approved by the Emory University Institutional Review Board.
View Source
Clinical Assessment. (Including new/updated results) 2.1 Medical assessment
View Source
Clinical Assessment. [Question: is this the same as pre-driver’s evaluation?] The administration of specific tools or instruments used during the first phase of the evaluation process for driving or community mobility. These may include an occupational profile and measures of performance skills, performance patterns, con- texts, activity demands, and client factors (AOTA, 2005 ).[ Add : Ma y also be referred t o as “ office based tests”].[ Comment : definition may not mee t ADED best practice guidelines]
View Source
Clinical Assessment. The participant will receive a comprehensive psychosocial assessment, including drug and alcohol use history and previous treatment, medical history, legal history, education and vocational history, family background, and mental health problems. At this appointment, the participant will be assessed for structured detoxification or medically supervised detoxification. Should the participant be in need of social or medical detoxification, he or she will be referred for these services through Substance Abuse Center of Kansas Detox/Sobering services which are co-located with COMCARE’s-Community Crisis Center. It is not unusual for participants to detoxify independently either during incarceration or in anticipation of adjudication. If the individual is not in need of structured detoxification, he or she will be placed in the appropriate level of treatment. Should the participant need a higher level of care such as inpatient residential treatment, the intake assessment counselor will make appropriate arrangements with available providers within the community. Referrals for inpatient/residential treatment outside of Sedgwick County will only be made if local provider resources are unavailable to appropriately meet the participant’s needs. To assist in the diagnostic process, assessment staff members utilize a number of substance use screening tools. In addition to utilizing the Texas Christian University’s Drug Screen II outlined above, staff members administer the Alcohol Use Disorders Identification Test (AUDIT-C) and the CAGE-AID assessment tool. The AUDIT-C has been proven accurate across all ethnic and gender groups, is a valid indicator for severity of alcohol use disorder and is most effective in identifying individuals with at risk, hazardous or harmful drinking. The CAGE-AID tool is a widely used screening test for problem drinking and potential alcohol problems. COMCARE-ATS recognizes the increase in gambling-related behaviors among the substance use disorders population. United States Department of Health and Human Services’ Substance Abuse and Mental Health Service Administration estimates that among clients with substance use disorders the rate of problem gambling is four to five times higher than the general population. As a result, ATS administers the Brief Bio-Social Gambling Screen (BBGS) to individuals who could benefit from problem gambling treatment services. ATS has two Kansas Certified Gambling Counselors assigned to this program who are ab...
View Source
Clinical Assessment. A professional evaluation of a participant’s mental health or emotional problems that may limit or preclude successful participation in a Welfare-to-Work plan.
View Source

Related to Clinical Assessment

  • Diagnostic Assessment 6.3.1 Boards shall provide a list of pre-approved assessment tools consistent with their Board improvement plan for student achievement and which is compliant with Ministry of Education PPM (PPM 155: Diagnostic Assessment in Support of Student Learning, date of issue January 7, 2013). 6.3.2 Teachers shall use their professional judgment to determine which assessment and/or evaluation tool(s) from the Board list of preapproved assessment tools is applicable, for which student(s), as well as the frequency and timing of the tool. In order to inform their instruction, teachers must utilize diagnostic assessment during the school year.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Risk Assessment An assessment of any risks inherent in the work requirements and actions to mitigate these risks.

  • Environmental Assessment Buyer shall have the right for a period commencing upon execution of this Agreement by both parties and ending on November 28, 2012, to conduct an environmental assessment of the Assets, at Buyer’s sole risk, liability and expense. Seller shall make available to Buyer, during the environmental assessment period described above, Seller’s historical files regarding prior operations on the Assets, and provide Buyer and its representatives with reasonable access to the Assets to conduct the environmental assessment. Buyer shall provide Seller three (3) days prior written notice of a desired date(s) for such assessment and Seller shall have the right to be present during any assessment and, if any testing is conducted pursuant to Seller’s express prior written consent, Seller may require splitting of all samples. Notwithstanding any other provision of this Agreement to the contrary, Buyer shall not have the right to drill any test, monitor or other ▇▇▇▇▇ or to extract samples of any air, soil, water or other substance from the Assets without Seller’s express prior written consent. If Buyer proposes a reasonable request to drill a test well or extract a sample pursuant to a systematic and customary procedure for the assessment of the environmental condition of the Assets and Seller refuses to grant its consent to such a well or sampling, then Buyer shall have the right, for a period of seventy-two (72) hours following notification of Seller’s refusal to consent, to deliver written notice to Seller of Buyer’s election to exclude from this transaction the portion of the Assets affected by such proposed test well or sample, and the Purchase Price shall be adjusted accordingly by the Allocated Value of such portion of the Assets so excluded. Under no circumstances whatsoever shall Seller ever be obligated to grant its consent to any such test ▇▇▇▇▇ or sampling proposed by Buyer, and Buyer’s sole and exclusive remedy for any refusal by Seller to grant its consent shall be the limited right contained in the preceding sentence to exclude the affected Assets from the transactions contemplated by this Agreement. If Buyer fails to exercise the right to exclude such Assets by written notice to Seller delivered prior to the expiration of the seventy-two hour period described above, then Buyer shall be conclusively deemed to have waived such right and shall be obligated to purchase the affected Assets without conducting such testing or sampling or any adjustment of the Purchase Price unless otherwise provided in this Agreement.

  • Environmental Assessment and Mitigation Development of a transportation project must comply with applicable environmental laws. The party named in article 1, Responsible Parties, under AGREEMENT is responsible for the following: A. The identification and assessment of any environmental problems associated with the development of a local project governed by this Agreement. B. The cost of any environmental problem’s mitigation and remediation. C. Providing any public meetings or public hearings required for the environmental assessment process. Public hearings will not be held prior to the approval of Project schematic. D. The preparation of the NEPA documents required for the environmental clearance of this Project. If the Local Government is responsible for the environmental assessment and mitigation, before the advertisement for bids, the Local Government shall provide to the State written documentation from the appropriate regulatory agency or agencies that all environmental clearances have been obtained.